European Network to Develop Policy Relevant Models and Socio-Economic Analyses of Drug Use, Consequences and Interventions: Final report: Part 1 - General Overview

Summary

This is the final overview report of a framework project which brought together and consolidating existing European networks of experts in prevalence estimation and dynamic modelling of drug use. The overall goal was to stimulate the development of tools to analyse data on drug use, its consequences, underlying social, economical, and health factors and processes and to explore the feasibility of applying them to evaluate policy options or interventions. According to the European Union funding conditions, funding was available for meetings and network coordination only. Therefore all work described was funded by other sources, including several EMCDDA funded projects that preceded or overlapped with the TSER network duration. The participating experts benefited from the presentations, discussions and contacts established at the meetings generated by this project.

This report is one of the outputs of a project funded by the European Commission, DG Research, Targeted Socio- Economic Resarch (TSER). Project no: ERB 4141 PL 980030, Contract no: SOE2-CT98- 3075 (Starting date: 1st December 1998 Duration: 36 months). 

Links to all seven parts of the report are available below:

Part 1: Overview

Part 2 National Level Prevalence Estimation 

Part 3 Local Level Prevalence Estimation

Part 4 Modelling Time trends and Incidence

Part 5 Modelling Geographic Spread withGeographic Information Systems (GIS) 

Part 6 Modelling Costs and Cost-effectiveness of Interventions

Part 7 Modelling Drug Markets and Policy options

Download as PDF

tser_overview.pdf

PDF files are made available as a convenience. In cases where the EMCDDA is not the originator of the document, please be aware that any PDFs available on this page may not be authoritative or there may be more recent versions available. While we make every effort to ensure that these files are definitive, before using or citing them, we recommend that you consult the publisher's website or contact the author(s) to check for more recent versions.

Abstract

This abstract is provided here as a convenience only. Check the publisher's website (if available) for the definitive version.

This is the final overview report of a framework project which brought together and consolidating existing European networks of experts in prevalence estimation and dynamic modelling of drug use.

The overall goal was to stimulate the development of tools to analyse data on drug use, its consequences, underlying social, economical, and health factors and processes and to explore the feasibility of applying them to evaluate policy options or interventions. According to the European Union funding conditions, funding was available for meetings and network coordination only. Therefore all work described was funded by other sources, including several EMCDDA funded projects that preceded or overlapped with the TSER network duration. The participating experts benefited from the presentations, discussions and contacts established at the meetings generated by this project.

The project had the following general objectives: a) Stimulate and consolidate newly existing multi- national networks of experts. b) Integrate complementary disciplines essential for studying drug use. c) Develop statistical and dynamic models of drug use, leading to improved prevalence estimates and analyses of spread, consequences, causes and interventions, and enhanced European comparability. d) Explore the feasibility of applying these models to evaluate policy options or interventions. e) Generate scientific publications and proposals for further research.

The network was subdivided in three areas: 1) Prevalence, 2) Dynamics and 3) Economic aspects of drug use. Two workgroups were formed within each area. These workgroups are: 1a “National level prevalence estimation”, 1b “Local level prevalence estimation”, 2a “Time trends and incidence”, 2b “Geographic spread”, 3a “Costs and cost-effectiveness”, and 3b “Drug markets and policy options”.

Additional information

This report was prepared by:

Lucas Wiessing, EMCDDA (project coordinator) Ludwig Kraus, IFT
Gordon Hay, Univ. Glasgow
Carla Rossi, Lucilla Ravà, Univ. Rome ‘Tor Vergata’ Martin Frischer, Heath Heatlie, Univ. Keele

Hans Jager, Wien Limburg, RIVM
Christine Godfrey, Univ. York
Chloé Carpentier, Monika Blum, Kajsa Mickelsson, Richard Hartnoll, EMCDDA

The above authors are the project and working group coordinators. The important input of all other network participants and invited experts is fully acknowledged. For a list of participants per working group and email contacts see Final Report Part 1, Annex A.

Other Network Participants and Invited Experts:
Erik van Ameijden, Fernando Antoñanzas, Rita Augustin, Ana Maria Bargagli, Massimiliano Bultrini, Marcel Buster, Maria Fe Caces, Maria Grazia Calvani, John Carnavale, Yoon Choi, Catherine Comiskey, Gloria Crispino O’Connell, Antonia Domingo- Salvany, Ken Field, Gerald Foster, Maria Gannon, David Goldberg, Peter Hanisch, Toon van der Heijden, Simon Heisterkamp, Matthew Hickman, Neil Hunt, Claude Jeanrenaud, Pierre Kopp, Petra Kümmler, Mirjam Kretzschmar, Marita van de Laar, Nacer Lalam, Fabio Mariani, Linda Nicholls, Alojz Nociar, Deborah Olzewski, Alessandra Nardi, Laetitia Paoli, Päivi Partanen, Paulo Penna, Harold Pollack, Maarten Postma, Thierry Poynard, Jorge Ribeiro, Francis Sartor, Janusz Sieroslawski, Ronald Simeone, Filip Smit, Juan Tecco, Alberto Teixeira, Jaap Toet, Gernot Tragler, Giovanni Trovato, Alfred Uhl, Julián Vicente, Katalin Veress, Denise Walckiers, Robert Welte, Ardine de Wit, John Wong, Tomas Zabransky, Terry Zobeck, Brigitta Zuiderma-van Gerwen.

Project funded by the European Commission, DG Research, Targeted Socio-Economic Resarch (TSER). Project no: ERB 4141 PL 980030, Contract no: SOE2-CT98-3075 Starting date: 1st December 1998
Duration: 36 months

Date of issue of this report: 31st January 2002

Top